دورية أكاديمية
Angiotensin receptor blockers are not associated with reduced inflammatory markers in the general population
| العنوان: | Angiotensin receptor blockers are not associated with reduced inflammatory markers in the general population |
|---|---|
| المؤلفون: | Marques-Vidal, Pedro, Vollenweider, Peter, Waeber, Gérard |
| المصدر: | Journal of Hypertension 33(10) 2173-2178 |
| سنة النشر: | 2015 |
| المجموعة: | Zenodo |
| مصطلحات موضوعية: | Angiotensin Receptor Antagonists/therapeutic use, Antihypertensive Agents/therapeutic use, Biomarkers/blood, C-Reactive Protein/metabolism, Inflammation/blood, Interleukin-1beta/blood, Interleukin-6/blood, Tumor Necrosis Factor-alpha/blood |
| الوصف: | OBJECTIVE: Angiotensin receptor blockers (ARBs) have been suggested to reduce inflammation in randomized controlled trials. We assessed the association between ARBs and inflammatory markers in a general population setting. METHODS: This is a population-based prospective study conducted in Lausanne, Switzerland. Baseline data from 933 participants on antihypertensive drugs (424 on ARBs) was collected in 2003-2006. Follow-up data from 1120 participants (572 on ARBs) was collected in 2009-2012. C-reactive protein (CRP), interleukins 1β and 6 and tumor necrosis factor alpha (TNF-α) were assessed and categorized in quartiles. RESULTS: At baseline, no differences were found between participants taking or not taking ARBs for all inflammatory markers studied, and this association persisted after multivariate adjustment: odds ratios (ORs) and (95% confidence interval) for being in the highest quartile of interleukin-1β, interleukin-6, TNF-α and CRP for participants on ARB compared to participants not on ARB were 1.23 (0.89-1.70), 1.26 (0.93-1.70), 1.14 (0.85-1.53) and 1.27 (0.96-1.69) respectively (P > 0.05). These findings were further replicated in the follow-up study: OR and (95% CI) of 1.10 (0.78-1.55), 0.87 (0.64-1.19), 0.83 (0.61-1.14) and 0.91 (0.68-1.22) for interleukin-1β, interleukin-6, TNF-α and CRP respectively (P > 0.05). Finally, no effect of ARBs was found when comparing participants who received ARBs throughout the 5.4-year follow-up with participants on other antihypertensive drugs: OR and (95% CI) of 0.93 (0.61-1.42), 0.80 (0.54-1.17), 0.86 (0.59-1.25) and 0.95 (0.67-1.35) for interleukin-1β, interleukin-6, TNF-α and CRP respectively (P > 0.05). CONCLUSION: ARBs are not associated with reduced levels of inflammatory markers in the general population. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | https://zenodo.org/communities/fbm_chuvTest; https://zenodo.org/record/211799Test; https://doi.org/10.1097/HJH.0000000000000683Test; oai:zenodo.org:211799 |
| DOI: | 10.1097/HJH.0000000000000683 |
| الإتاحة: | https://doi.org/10.1097/HJH.0000000000000683Test https://zenodo.org/record/211799Test |
| حقوق: | info:eu-repo/semantics/openAccess ; https://creativecommons.org/licenses/by-nc-nd/4.0/legalcodeTest |
| رقم الانضمام: | edsbas.B4DB10A5 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/HJH.0000000000000683 |
|---|